Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives

Junjun Li; Li Liu; Jingbo Zhang; Xiang Qu; Takuji Kawamura; Shigeru Miyagawa; Yoshiki Sawa

doi:10.3390/bioengineering9110605

Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives

Bioengineering (Basel). 2022 Oct 22;9(11):605. doi: 10.3390/bioengineering9110605.

Authors

Junjun Li¹, Li Liu¹, Jingbo Zhang¹, Xiang Qu¹, Takuji Kawamura¹, Shigeru Miyagawa¹, Yoshiki Sawa²

Affiliations

¹ Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
² Cardiovascular Division, Osaka Police Hospital, Tennoji, Osaka 543-0035, Japan.

Abstract

Heart failure (HF) is the leading cause of death worldwide. The most effective HF treatment is heart transplantation, the use of which is restricted by the limited supply of donor hearts. The human pluripotent stem cell (hPSC), including human embryonic stem cell (hESC) and the induced pluripotent stem cells (hiPSC), could be produced in an infinite manner and differentiated into cardiomyocytes (CMs) with high efficiency. The hPSC-CMs have, thus, offered a promising alternative for heart transplant. In this review, we introduce the tissue-engineering technologies for hPSC-CM, including the materials for cell culture and tissue formation, and the delivery means into the heart. The most recent progress in clinical application of hPSC-CMs is also introduced. In addition, the bottleneck limitations and future perspectives for clinical translation are further discussed.

Keywords: cardiac regeneration; cardiomyocytes; heart failure; human induced pluripotent stem cells; tissue engineering.

Publication types

Review

Grants and funding

This research was funded by the Japan Society for the Promotion of Science (JSPS), grant numbers 22K12801, 20H00542, and 22H03157; and the Japan Agency for Medical Research and Development (AMED), grant numbers 22bm0804008h and 22mk0101226h.